When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

When hormone therapy stops working, the cancer is said to be “castration resistant.” On average, it takes about two years for prostate cancer to become resistant to hormone therapy ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

ADT, androgen-deprivation therapy; DOC, docetaxel; FDA, US Food and Drug Administration; mHSPC, metastatic hormone-sensitive prostate cancer; RCT, randomized controlled trial. We considered the ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

2. Ovarian Cancer: Research indicates that a woman's chance of developing ovarian cancer may be influenced by hormonal ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with robust clinical trial evidence on the benefits of combining androgen-deprivation therapy (ADT) with androgen receptor ...